Exelixis, Inc. - Common Stock (NQ:EXEL)

58.61 +0.22 (+0.38%)

Delayed Quote Updated: 12:25 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Exelixis: Q4 Earnings Insights ↗

February 17, 2022

Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings...

Via Benzinga

Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

February 17, 2022

From Exelixis, Inc.

Via Business Wire

Earnings Scheduled For February 17, 2022 ↗

February 17, 2022

Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.

Via Benzinga

Earnings Preview For Exelixis ↗

February 16, 2022

Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will...

Via Benzinga

Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial ↗

February 15, 2022

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (...

Via Benzinga

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

February 14, 2022

From Bristol Myers Squibb

Via Business Wire

Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022

February 03, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022

February 02, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022

January 18, 2022

From Exelixis, Inc.

Via Business Wire

The Sunday File for Nov. 21 ↗

November 21, 2021

Good news and bad - making up for the short week by getting a Sunday start.

Via Talk Markets

Analyst Ratings For Exelixis ↗

November 03, 2021

Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ:

Via Benzinga

Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗

January 10, 2022

Pfizer and Bayer inked deals with several companies in gene-editing.

Via Investor's Business Daily

A Peek Into The Markets: US Stock Futures Edge Higher; Crude Oil Up 0.5% ↗

January 10, 2022

Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the three major averages recorded losses last week. Investors are awaiting earnings...

Via Benzinga

Early Monday Report - More Moves Out Of China ↗

January 09, 2022

Before it even turned Monday in the West, China insurers are feeling the heat.

Via Talk Markets

Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022

January 09, 2022

From Exelixis, Inc.

Via Business Wire

Post-Fed Thursday ↗

January 06, 2022

Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.

Via Talk Markets

Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

January 06, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma

January 05, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022

January 04, 2022

From Exelixis, Inc.

Via Business Wire

Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

January 04, 2022

From Exelixis, Inc.

Via Business Wire

7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now ↗

January 03, 2022

These cheap stocks are trading at highly attractive prices and have the potential to break through this year.

Via InvestorPlace

The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗

December 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...

Via Benzinga

Exelixis Elects Jacqueline Wright to Its Board of Directors

December 17, 2021

From Exelixis, Inc.

Via Business Wire

Uncertain Times ↗

December 15, 2021

The UK inflation rate last month was 5.1%, not a good omen.

Via Talk Markets

Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors

December 15, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021

November 20, 2021

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer

November 09, 2021

From Exelixis, Inc.

Via Business Wire

3 No-Brainer Biotech Stocks to Buy in November ↗

November 04, 2021

Here are three Motley Fool contributors' top picks.

Via The Motley Fool

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December

November 03, 2021

From Exelixis, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 03, 2021

Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.